Core Viewpoint - The strategic investment by Baiyang Pharmaceutical in Beihai Kangcheng marks a significant partnership aimed at enhancing the commercialization of rare disease drugs, with Baiyang becoming the largest shareholder without seeking control [1][4]. Group 1: Investment Details - Beihai Kangcheng's stock price surged by 34.13% following the announcement of the strategic cooperation and investment from Baiyang Pharmaceutical [2]. - Baiyang Pharmaceutical will subscribe to 74.9715 million new shares of Beihai Kangcheng at a price of HKD 1.34 per share, totaling HKD 100 million, which represents a discount of approximately 19.76% compared to the last closing price of HKD 1.67 before trading suspension [3]. - After the subscription, the new shares will account for about 17.65% of Beihai Kangcheng's existing issued share capital and 14.99% of the enlarged share capital [3]. Group 2: Company Profiles - Baiyang Pharmaceutical is an A-share listed company engaged in pharmaceutical distribution, with its core business divided into brand operation, wholesale distribution, and retail [4]. - Beihai Kangcheng focuses on the research and development of drugs for rare diseases, currently holding a portfolio of 10 drug assets, including 3 approved products and 7 in development [4]. - The company recently received approval for its enzyme replacement therapy, which is the first domestically developed treatment for Gaucher disease in China [4]. Group 3: Strategic Collaboration - In addition to the equity investment, Baiyang Pharmaceutical and Beihai Kangcheng have established an exclusive commercial service agreement to expand their strategic cooperation [5]. - A subsidiary of Baiyang Pharmaceutical will act as the exclusive commercial service provider for specific products in mainland China, Hong Kong, and Macau, with options for distribution [5]. - The founder and CEO of Beihai Kangcheng emphasized that Baiyang's extensive network and strong business capabilities will facilitate market penetration for their existing products, with the financing aimed at advancing commercialization and improving operational efficiency [5].

8月13日，智通财经记者获悉，北海康成与百洋医药达成股份认购协议，百洋医药将以每股1.34港元的 价格认购价值约1亿港元的股份，约7497万股。与此同时，北海康成还与百洋医药签订了独家商业化服 务协议，百洋医药旗下子公司将获得北海康成旗下特定产品在中国大陆、香港及澳门地区的推广权。 ...

Group 1 - Kangji Medical (09997) resumed trading with a nearly 1% increase, announcing a privatization agreement with Knight Bidco Limited, which will make Kangji a wholly-owned subsidiary and delist from the Hong Kong Stock Exchange after completion [1] - Tencent Music (01698) opened high with over a 15% increase, reporting a 30% year-on-year increase in adjusted net profit for Q2 ending June 30, 2025, driven by high-quality growth in its online music business [1] - Mingyuan Cloud (00909) opened over 2% higher, announcing a cash acquisition of 100% equity in ASIOT Co., Ltd. for 700 million yen by its subsidiary MytePro Japan [1] Group 2 - Yuedu Group (00772) surged over 15%, reporting a 68.5% year-on-year increase in net profit for the first half of the year, with strong performance in IP for premium films and animations, and significant growth in the emerging short drama sector [2] - Minmetals Resources (01208) rose over 9%, with net profit increasing 15 times year-on-year, attributed to higher copper production and rising prices of copper, gold, silver, and zinc [2] - Beihai Kangcheng-B (01228) increased over 31%, announcing a strategic cooperation agreement with Baiyang Pharmaceutical for exclusive commercial services in promoting several products in mainland China, Hong Kong, and Macau [2] Group 3 - Zhonghui Biotech-B (02627) surged over 25%, as its vaccine product was included in the preliminary review list of the national commercial health insurance innovative drug catalog [2] - Gilead Sciences-B (01672) rose over 5%, announcing promising efficacy results for its candidate drug ASC47 in combination with teriparatide for obesity treatment in diet-induced obesity mouse studies [3] - Dongying Travel (06882) fell over 9%, issuing a profit warning with expected net profit of approximately 6 million HKD for the first half of 2025, down about 82% from 34 million HKD in the same period last year [3] Group 4 - Kodak (KODK.US) dropped 19.91% after reporting a shift from profit to loss in Q2, raising concerns about its ability to execute critical financing measures [4] - Niu Technologies (NIU.US) rose 11.69%, reporting a turnaround to profitability in Q2 and projecting Q3 revenue between 1.433 billion to 1.638 billion CNY, a year-on-year increase of 40% to 60% [4] - Huya (HUYA.US) increased by 4.53%, preparing to release its financial report, with a strong growth trajectory in gaming-related services [4] Group 5 - ON Running (ONON.US) rose 8.95%, reporting a 32% year-on-year increase in Q2 sales and projecting annual net sales of at least 2.91 billion Swiss francs, exceeding previous expectations [6] - Micron Technology (MU.US) increased by 3.26%, significantly raising its Q4 fiscal year 2025 revenue guidance to between 11.1 billion to 11.3 billion USD, with gross margin guidance improved to 44% to 45% [6]

Group 1 - The company announced the issuance of 74.97 million new shares to Baiyang Pharmaceutical at a price of HKD 1.34 per share, representing a discount of 19.76% compared to the last trading price before suspension [1] - The net proceeds from the subscription amount to approximately HKD 98.66 million, which will be used for the development of commercialized products, marketing and promotional activities, loan repayment, and daily operations [1] - After the completion of the transaction, Baiyang Pharmaceutical will hold 14.99% of the company's equity, and the latter has stated that it has no intention to acquire any controlling stake in the company within three years [1] Group 2 - The company's stock price rose by 25.15% in early trading, currently reported at HKD 2.09, with a trading volume of HKD 29.23 million [2]

北海康成-B(01228)再涨超12%，截至发稿，涨11.98%，报1.87港元，成交额1844.94万港元。 同时，公司两家附属与百洋医药股份附属百洋附属订立一份战略合作及独家商业服务协议。据此，相关 附属同意委任百洋附属为独家合同销售组织，于内地、香港及澳门推广集团的若干产品。 消息面上，北海康成公布，向百洋医药（301015）(301015.SZ)发行7497万股新股，每股作价1.34港元， 较停牌前收报折让19.76%，认购事项所得款项净额约9866.18万港元，拟用于商业化产品的研发；营销 及推广活动；偿还贷款融资；及日常营运。完成后，百洋医药将持有公司股本14.99%，后者已表示其 无意于三年内收购公司任何控股股份。 ...

Core Viewpoint - Beihai Kangcheng-B (01228) has seen a significant increase in stock price, rising over 12% to HKD 1.87, with a trading volume of HKD 18.44 million [1] Group 1: Financial Actions - Beihai Kangcheng announced the issuance of 74.97 million new shares to Baiyang Pharmaceutical (301015.SZ) at a price of HKD 1.34 per share, representing a discount of 19.76% compared to the last trading price before suspension [1] - The net proceeds from the subscription amount to approximately HKD 98.66 million, which will be used for the development of commercialized products, marketing and promotional activities, loan repayment, and daily operations [1] Group 2: Strategic Partnerships - The company has entered into a strategic cooperation and exclusive commercial service agreement with subsidiaries of Baiyang Pharmaceutical, designating Baiyang's subsidiary as the exclusive sales organization for promoting several of the group's products in mainland China, Hong Kong, and Macau [1] - Following the share issuance, Baiyang Pharmaceutical will hold 14.99% of Beihai Kangcheng's equity, and it has stated that it does not intend to acquire any controlling stake in the company within the next three years [1]

Group 1 - North Sea Kangcheng-B signed a subscription agreement with Baiyang Health Industry International Trade Co., Ltd. to issue 74.9715 million shares at HKD 1.34 per share, representing a discount of approximately 19.76% compared to the previous trading day's closing price [2] - The subscription is expected to raise HKD 100 million, with net proceeds estimated at approximately HKD 98.6618 million, which will be used for product research and development, marketing promotion, loan repayment, and daily operations [2] - The company's shares will be suspended from trading starting at 9:00 AM on August 12, 2025, and will resume trading at 9:00 AM on August 13, 2025 [2]

格隆汇8月13日丨北海康成-B(01228.HK)发布公告，该公司的股份将于今天(13/8/2025)上午九时正起恢 复买卖。 ...

Core Viewpoint - Beihai Kangcheng-B (01228) has entered into a subscription agreement with Baiyang Health Industry International Trade Co., Ltd. to issue 74.9715 million shares at a subscription price of HKD 1.34 per share, representing a discount of approximately 19.76% from the closing price of HKD 1.67 on August 11, 2025 [1] Group 1 - The total amount raised from the subscription will be HKD 100 million, with a net amount of approximately HKD 98.6618 million after deducting related expenses [1] - The net proceeds from the subscription will be used for (i) research and development of commercialized products; (ii) marketing and promotional activities; (iii) repayment of loan financing and borrowings; and (iv) daily operations of the group [1] - Trading of the shares has been suspended on the Hong Kong Stock Exchange from 9:00 AM on August 12, 2025, at the company's request, with a resumption of trading expected on August 13, 2025 [1]

Core Viewpoint - The company, 北海康成-B (01228), has entered into a subscription agreement with 百洋健康产业国际商贸有限公司 to issue 74.9715 million shares at a subscription price of HKD 1.34 per share, representing a discount of approximately 19.76% from the closing price of HKD 1.67 on August 11, 2025 [1] Group 1 - The total amount raised from the subscription will be HKD 100 million, with a net amount estimated at approximately HKD 98.6618 million after deducting related expenses [1] - The net proceeds from the subscription are intended to be used for (i) research and development of commercialized products; (ii) marketing and promotional activities; (iii) repayment of loan financing and borrowings; and (iv) general operational activities of the group [1] - Trading of the company's shares was suspended on the Hong Kong Stock Exchange from 9:00 AM on August 12, 2025, at the request of the company, pending the announcement [1]